Anika Therapeutics (ANIK) director nets RSU shares after tax withholding

Rhea-AI Filing Summary

Anika Therapeutics director Cheryl R. Blanchard reported the vesting of 20,001 restricted stock units into common shares. Each RSU converts into one share of common stock, and this represents the third and final installment of a 60,004-unit award granted on March 9, 2023.

Of the vested shares, 5,871 were withheld by the company at $14.96 per share to cover tax obligations, leaving a net increase of 14,130 shares. Following these transactions, Blanchard holds 211,450 shares directly and an additional 11,742 shares indirectly through a revocable trust of which she is the sole trustee and a beneficiary.

Insider Trade Summary

20,001 shares exercised/converted

Mixed 4 txns

Insider Blanchard Cheryl R

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Unit	20,001	$0.00	--
Exercise	Common Stock	20,001	$0.00	--
Tax Withholding	Common Stock	5,871	$14.96	$88K
holding	Common Stock	--	--	--

Holdings After Transaction: Restricted Stock Unit — 0 shares (Direct); Common Stock — 217,321 shares (Direct); Common Stock — 11,742 shares (Indirect, Revocable Trust)

Footnotes (1)

1. Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock. Reflects an aggregate of 5,871 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 9, 2026. Consists of shares held by The Cheryl R. Blanchard Amended and Restated Revocable Trust dated December 19, 2014, of which the Reporting Person is a beneficiary and the sole trustee. On March 9, 2023, the Reporting Person was granted 60,004 RSUs vesting in three equal annual installments beginning on March 9, 2024. This transaction reflects the third and final vesting installment of such RSU award.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Blanchard Cheryl R

(Last) (First) (Middle)

C/O ANIKA THERAPEUTICS, INC.

32 WIGGINS AVENUE

(Street)

BEDFORD MA 01730

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Anika Therapeutics, Inc. [ ANIK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/09/2026		M		20,001	A	(1)	217,321	D
Common Stock	03/09/2026		F		5,871(2)	D	$14.96	211,450	D
Common Stock								11,742	I	Revocable Trust(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	03/09/2026		M			20,001	(4)	(4)	Common Stock	20,001	$0	0	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock.

2. Reflects an aggregate of 5,871 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 9, 2026.

3. Consists of shares held by The Cheryl R. Blanchard Amended and Restated Revocable Trust dated December 19, 2014, of which the Reporting Person is a beneficiary and the sole trustee.

4. On March 9, 2023, the Reporting Person was granted 60,004 RSUs vesting in three equal annual installments beginning on March 9, 2024. This transaction reflects the third and final vesting installment of such RSU award.

	/s/ Cheryl R. Blanchard	03/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Cheryl R. Blanchard report at Anika Therapeutics (ANIK)?

Cheryl R. Blanchard reported the vesting and conversion of 20,001 restricted stock units into common shares. These RSUs were part of a 60,004-unit grant made on March 9, 2023, vesting in three equal annual installments beginning March 9, 2024.

How many Anika Therapeutics (ANIK) shares were withheld for taxes in this Form 4?

Anika Therapeutics retained 5,871 common shares to satisfy tax withholding obligations on vested RSUs. The shares were valued at $14.96 each for this purpose, reducing the net shares added to Cheryl R. Blanchard’s direct holdings from the 20,001 vested units.

What RSU award is this Form 4 transaction related to for Anika Therapeutics (ANIK)?

The transaction relates to a 60,004-unit RSU grant awarded on March 9, 2023. The grant vests in three equal annual installments starting March 9, 2024, and this Form 4 reflects the third and final 20,001-unit vesting installment from that award.

What are Cheryl R. Blanchard’s direct and indirect Anika Therapeutics (ANIK) holdings after this filing?

After the reported transactions, Cheryl R. Blanchard directly owns 211,450 shares of Anika Therapeutics common stock. She also has indirect ownership of 11,742 shares held by The Cheryl R. Blanchard Amended and Restated Revocable Trust, where she is the sole trustee and a beneficiary.

Was this Anika Therapeutics (ANIK) insider transaction an open-market stock purchase or sale?

No, the activity reflects RSU vesting and a tax-withholding share disposition, not an open-market trade. RSUs converted into common shares at no exercise price, and a portion of those shares was retained by Anika Therapeutics to cover tax obligations associated with the vesting.

How many RSUs did Anika Therapeutics (ANIK) director Blanchard exercise in this Form 4?

Cheryl R. Blanchard exercised 20,001 restricted stock units into an equal number of common shares at an exercise price of $0.00. This represents the final one-third of a 60,004-unit RSU grant initially awarded on March 9, 2023 under her equity compensation.